Evaluation of ABO blood group as a prognostic marker in renal cell carcinoma (RCC).
OBJECTIVE
To evaluate ABO blood group as a prognostic marker in patients with renal cell carcinoma (RCC).


METHODS
This retrospective study included 556 consecutive patients who underwent surgery for RCC at a single institution. The associations of ABO blood group with clinical and pathological variables were assessed using Kruskal-Wallis and chi-squared tests. The impact on overall survival (OS) and RCC-specific survival (RCC-SS) was analysed using univariable and multivariable Cox proportional hazards regression models.


RESULTS
Blood group O was associated with the absence of lymph node metastases (P = 0.034) and the presence of bilateral RCC (P = 0.017). No associations with age, gender, body mass index, Charlson comorbidity index, T stage, M stage, grade and histological subtype were observed. In univariable and multivariable survival analysis, ABO blood group was not associated with OS and RCC-SS.


CONCLUSIONS
In the present study, ABO blood group was not linked with RCC prognosis. Blood group O may be associated with the absence of lymph node metastases and the presence of bilateral RCC. External validation in larger cohorts is necessary.
Department of Urology, Medical University of Vienna, Vienna, Austria.
Michela
M
de Martino
Matthias
M
Waldert
Andrea
A
Haitel
Georg
G
Schatzl
Shahrokh F
SF
Shariat
Tobias
T
Klatte
D000017:ABO Blood-Group System; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D002292:Carcinoma, Renal Cell / Q000097:blood*; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies
D000017:ABO Blood-Group System; D014408:Biomarkers, Tumor
ABO; blood group; blood type; prognosis